Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Significant Growth in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 35,983 shares, an increase of 221.2% from the December 31st total of 11,203 shares. Based on an average daily volume of 179,753 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are short sold. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 179,753 shares, the short-interest ratio is presently 0.2 days.

Fresenius SE & Co. Trading Down 4.1%

Shares of OTCMKTS FSNUY traded down $0.61 during trading hours on Wednesday, hitting $14.29. The company’s stock had a trading volume of 3,090 shares, compared to its average volume of 83,199. Fresenius SE & Co. has a 12 month low of $9.50 and a 12 month high of $33.93. The stock has a market cap of $32.19 billion, a price-to-earnings ratio of 25.98 and a beta of 0.76. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.99 and a current ratio of 1.26. The business has a 50-day simple moving average of $14.13 and a 200-day simple moving average of $14.02.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.02. The business had revenue of $6.29 billion during the quarter, compared to analysts’ expectations of $6.38 billion. Fresenius SE & Co. had a return on equity of 9.72% and a net margin of 5.26%. On average, analysts anticipate that Fresenius SE & Co. will post 0.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on FSNUY shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research report on Monday, October 27th. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, December 15th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Fresenius SE & Co. presently has a consensus rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.